Tapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic and Bariatric Surgery

NCT07859176 on ClinicalTrials.gov · last registry update 2026-10-05

Registered but not yet open, with 100 participants planned. Due to report April 2028, alongside 31 other tracked readouts that quarter. Primary outcome, as filed: Percentage change in body weight. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.

Status: NOT_YET_RECRUITING
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: General Committee of Teaching Hospitals and Institutes, Egypt
Sponsor type: Other Gov
Enrollment: 100
Started: 2026-10
Primary completion: 2028-04 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Detected	Change	Detail
2026-10-05	First seen in registry	Registered as NOT_YET_RECRUITING, P4

Primary outcome

Percentage change in body weight

Conditions studied

Morbid Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.